Table 3: Linear regression controlling known metabolic syndrome covariates with a subset of study participants with metabolic syndrome.

MetS Subsample

 

Model 1a

 

 

Model 2b

 

 

Model 3c

 

Coefficient

B

SE B

p-value

B

SE B

p-value

B

SE B

p-value

Intercept

3.618

0.485

< 0.0001

4.574

0.603

< 0.0001

0.334

0.858

0.700

Fasting glucose (mg/dL)

-0.005

0.001

< 0.0001

-0.007

0.001

< 0.0001

-0.006

0.001

< 0.001

Triglycerides (mg/dL)

0.001

0.000

0.059

0.001

0.000

0.001

0.001

0.001

0.033

HDL (mg/dL)

-0.013

0.003

< 0.001

-0.004

0.003

0.194

-0.002

0.005

0.705

Systolic BP (mmHg)

0.005

0.002

0.009

0.006

0.002

0.019

0.008

0.003

0.018

Diastolic BP (mmHg)

-0.001

0.003

0.663

-0.005

0.004

0.174

-0.001

0.005

0.794

WC (cm)

0.024

0.003

< 0.0001

0.011

0.009

0.194

0.019

0.009

0.045

R2

 

0.116

 

 

0.245

 

 

0.350

 

Models demonstrating the influence of metabolic risk factors on uric acid (UA) level in the subsample with metabolic syndrome. Beta values (B) are expressed in mg/dL of serum uric acid. a: Unadjusted model demonstrating the influence of each metabolic risk factor on UA levels; b: Model adjusted for sex, race, hs-CRP, BMI, HOMA-IR, and smoking; c: Model adjusted for the same variables as model 2 with the addition of physical activity, blood urea nitrogen, serum creatinine, alanine aminotransferase (ALT), and prescription medications that treat hyperuricemia